TNF/TIL human gene therapy clinical protocol.
D026683:Advisory Committees; D000818:Animals; D002478:Cells, Cultured; D003131:Combined Modality Therapy; D026724:Ethical Review; D035082:Federal Government; D015316:Genetic Therapy; D005822:Genetic Vectors; D033161:Government Regulation; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000494:pharmacology; D016246:Lymphocytes, Tumor-Infiltrating / Q000637:transplantation*; D008253:Macaca mulatta; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000628:therapy*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D012107:Research Design; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D014481:United States
D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha